← Back
Attovia Therapeutics
ATTO · listed on Nasdaq · worth $684.77 million
$15.27
−3.35% on Oct 29
Eight insider buys in the last year, $42.37 million in all. None in the last two weeks.
Different buyers at onceDirector Colin Walsh bought, and Deep Track Capital reported a new 7.5% stake, within a day · Aug 13
Green dot = an insider bought red = soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
26.3M shares
58% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, five insiders bought Attovia Therapeutics stock and two insiders sold. None of the 46 sales is marked on its filing as planned in advance. The biggest seller was Colin Walsh.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
Colin Walsh
Bought $8.5M on Aug 6 — 500,000 shares at $17.00, held through a trust or family, 17% of what they now own.
No earlier purchases to measure
Insider
Goldman Sachs Group
Bought $8.5M on Aug 6 — 500,000 shares at $17.00, held through a trust or family, 17% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
10% owner
Redmile Group
Bought $6.8M on Aug 6 — 400,000 shares at $17.00, held through a trust or family, 34% of what they now own.
No earlier purchases to measure
Planned sales
Form 144 notices filed for Attovia Therapeutics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Former officer Goldman Sachs Group filed to sell 105,807 shares on 28 Aug; no sale reported yetNotice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Attovia Therapeutics, newest first.
All reports
Every insider trade and SEC report we hold for Attovia Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 13BoughtColin WalshAug 13 · Traded Aug 6 · Director+17%via a trust or family500,000 @ $17.00$8.5M
49 more with Pro →Analysts, earnings and news
Analysts' price target
$42.20 average
5 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
0 of 1 quarters above
Q2 '26−$4.88 a share−$0.26